title: [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
abstract: OBJECTIVE
  To compare the differences in clinical therapeutic effect and safety between amphotericin B and its liposome form in treating invasive fungal infection (IFI) in hematological disorder with neutrocytopenia.
  
  
  METHODS
  Of 111 patients with IFI, 82 were treated with amphotericin B and 29 with amphotericin B liposome. The mean cumulative dose of amphotericin B was 617 (60-1895) mg and the mean course was 18 (7-60) d, and those for amphotericin B liposome was 925 (140-3420) mg and 13 (7-50) d, respectively.
  
  
  RESULTS
  The total effective rates of amphotericin B and its liposome groups were 69% and 58%, respectively (P>0.05). The adverse effect rates of chill and fever in amphotericin B and its liposome groups were 21% and 10% (P>0.05), hypopotassemia 34% and 14% (P=0.03), hepatic impairment 22% and 17% (P>0.05), and renal impairment 9% and 3%, respectively (P>0.05).
  
  
  CONCLUSIONS
  The therapeutic effect for IFI of amphotericin B and its liposome was similar. The severe adverse reaction of amphotericin B liposome was slightly lower than that of amphotericin B.
authors.affiliation: The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Tong
authors.forename: Feng-juan
authors.initials: FJ
authors.lastname: Zhang
authors.forename: Feng
authors.initials: F
authors.lastname: Xiao
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Qian
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Meng
authors.forename: Wen-yuan
authors.initials: WY
authors.lastname: Mai
authors.forename: Yin
authors.initials: Y
authors.lastname: Tong
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Mao
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000380:Agranulocytosis / Q000150:complications; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage / Q000627:therapeutic use; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B